TUCSON, AZ–(Marketwired – Apr 7, 2014) – HTG Molecular Diagnostics, Inc., (HTG) and OvaGene Oncology have entered a manufacturing supply agreement where OvaGene will design and develop their proprietary gene expression assays on HTG’s fully automated, extraction-free Edge Platform.
The HTG Edge System is the only extraction-free, automated gene expression platform that delivers affordable, multiplexed results on lysed samples in less than a day. The Edge System’s multiplexing capability utilizing only one five-micron thick FFPE section provides a unique solution for the clinical laboratory professional.
OvaGene Oncology is entirely dedicated to helping women with gynecologic cancers by providing their treating oncologists with molecular tests developed using the latest advancements in gene-based diagnostics. Each year in the USA there are approximately 84,000 women diagnosed with a gynecologic cancer: 22,000 cases of ovarian cancer; 52,000 cases of endometrial cancer; and, 12,000 cases of cervical cancer.
“We are thrilled to partner with OvaGene as they commercialize these novel molecular tests to make a difference with cancer patients,” stated TJ Johnson, HTG CEO.
“We recognized right away that HTG’s technology would help us improve our workflow and reduce turnaround time to our customers and ultimately patients while providing superior quality data. In addition, the system will allow us to expand our specimen type to ascites and smaller samples such as biopsies,” commented Frank Kiesner, CEO of OvaGene.
About HTG:
Headquartered in Tucson, Arizona, HTG Molecular Diagnostics’ mission is to provide simple, cost effective solutions for accurate RNA testing. In 2013 the company commercialized its Edge instrument platform and a portfolio of mRNA assays that leverage HTG’s proprietary nuclease protection chemistry. The capability of the Edge System has been expanded to fully automate sample and targeted library preparation for next-generation sequencing.
About OvaGene Oncology Inc.
OvaGene is a molecular diagnostics company located in Irvine, California dedicated to improving cancer care and outcomes for gynecologic cancer patients through the development of novel gene-based assays. Through its CLIA Lab, the company offers a menu of tests including gene-based diagnostic assays to assist physicians in the prognosis of gynecologic cancers as well as therapy selection, including radiation and chemotherapy. Visit www.ovagene.com for more information.
Contact:
Kimberly Schmitz
(HTG Molecular)
Communications Consultant
Spur Public Relations
Phone: 520-247-5778
Email: Email Contact
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: Email Contact